Targeted Therapy Combination Shows Promising Antitumor Activity in Aggressive Meningiomas
PHILADELPHIA — The targeted therapy combination of the mTOR inhibitor everolimus (Afinitor) and the somatostatin agonist octreotide (Sandostatin) yielded...
Search/Filter
Loading...
Adolescent and Young Adult Cancer Survivors May Have an Elevated Risk of Hospitalizations
PHILADELPHIA — Adolescent and young adults who survived at least two years after a cancer diagnosis had nearly double...
New AACR Journal, Blood Cancer Discovery, Publishes Its First Paper
Study reports the landscape of mutations present in pediatric acute lymphoblastic leukemia (ALL) and how this landscape changes during...
American Cancer Survivors Face Substantial Financial Hardship and Financial Sacrifices
PHILADELPHIA —American cancer survivors, particularly those 64 years or younger, faced substantial medical financial hardship and sacrifices in spending,...
Circulating Tumor DNA May Be Predictive of Disease Progression in Patients with Rectal Cancer
PHILADELPHIA — Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemoradiotherapy was associated with poor response and increased risk...
BRAF Inhibitor Shows Promising Results in Pediatric Patients with Low-Grade Glioma
PHILADELPHIA — Dabrafenib (Tafinlar), a BRAF inhibitor approved to treat certain types of adult melanoma, showed activity in pediatric...
Anti-CTLA-4 Antibody Tremelimumab Shows Efficacy in Patients With Metastatic Bladder Cancer
PHILADELPHIA — Treatment with the investigational anti-CTLA-4 agent tremelimumab showed clinical responses in patients with pretreated metastatic bladder cancer,...
Commercial Prognostic Tests for Prostate Cancer May Not Be Accurate in African American Men
PHILADELPHIA — Commercial gene expression tests that guide treatment decisions for prostate cancer may not accurately predict risk of...
Oncotype DX Breast Recurrence Score Reveals Sex-related Differences in Mortality Prediction in Patients With Early-stage ER-positive Breast Cancer
PHILADELPHIA — The associations of breast cancer recurrence scores (RS) with mortality measured using Oncotype DX, a commercial diagnostic...
Long-term Survival Rate for Subset of Patients With Advanced Melanoma Following BRAF- and MEK-targeted Treatment Combination Higher Than Historical Rate
PHILADELPHIA — Almost 40 percent of patients with metastatic melanoma harboring BRAF V600E mutations who were treated with a...